Immutep expands Part C of TACTI-002 due to positive data
Filed with ASX · · 2 pages · English
In the deck
Earlier from Immutep
- INSIGHT-004 clinical trial update
- Immutep announces European patent grant for LAG525 antibody
- Appendix 4C - quarterly
- Immutep presents positive TACTI-mel melanoma trial data
- Immutep receives A$2.5M R&D French Tax Incentive
Later from Immutep
- Immutep Activities Report
- Immutep reports positive TACTI-002 data
- Immutep receives 2nd IND approval for efti from US FDA
- Immutep reports supportive efficacy data from AIPAC study
- Immutep AIPAC Ph2b Clinical Results & Update Webcast Slides
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep